J&J has offered to contribute $2 billion toward resolving remaining talc litigation as part of the newly created subsidiary’s bankruptcy reorganization.

FDA approves J&J's Tremfya for its fourth indication and the second IBD condition.

Johnson & Johnson’s failure to resolve mass tort talc litigation through the US bankruptcy system wasn’t just a setback for the health-care giant, but also a costly blow for plaintiffs’ lawyers ...

Cocoa on the web: 280 North, Objective-J, and Cappuccino SproutCore is but one complete, pure JavaScript framework for building web- … ...

Contribute to j-0no/odin-project-javascript-exercises development by creating an account on GitHub.